Aptamers as candidate therapeutics for cardiovascular indications.
The first therapeutic aptamer was approved for human use in 2004, and a range of chemical substitutions that improve the drug-like properties of aptamers has recently been shown to increase the utility of this modality. Currently there are both anticoagulant and antithrombotic aptamers in the clinic, and additionally there are a number of earlier stage projects in which a variety of cardiovascular targets are inhibited by specific aptamers and for which a wide range of therapeutic applications has been suggested.
Keefe
Anthony D
AD
Archemix Corporation, 300 Third Street, Cambridge, MA 02142, USA. keefe@archemix.com
Schaub
Robert G
RG
D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology; D052157:Aptamers, Nucleotide / Q000494:pharmacology* / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000503:physiopathology; D002448:Cell Adhesion / Q000187:drug effects; D016503:Drug Delivery Systems; D005343:Fibrinolytic Agents / Q000494:pharmacology; D006801:Humans
D000925:Anticoagulants; D052157:Aptamers, Nucleotide; D002317:Cardiovascular Agents; D005343:Fibrinolytic Agents